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Abstract
The neuronal ceroid lipofuscinoses are a group of lysosomal storage disorders that com-
prise the most common, genetically heterogeneous, fatal neurodegenerative disorders of
children. They are characterised by childhood onset, visual failure, epileptic seizures, psy-
chomotor retardation and dementia. CLN3 disease, also known as Batten disease, is
caused by autosomal recessive mutations in the CLN3 gene, 80–85% of which are a ~1 kb
deletion. Currently no treatments exist, and after much suffering, the disease inevitably
results in premature death. The aim of this study was to generate a zebrafish model of
CLN3 disease using antisense morpholino injection, and characterise the pathological and
functional consequences of Cln3 deficiency, thereby providing a tool for future drug discov-
ery. The model was shown to faithfully recapitulate the pathological signs of CLN3 disease,
including reduced survival, neuronal loss, retinopathy, axonopathy, loss of motor function,
lysosomal storage of subunit c of mitochondrial ATP synthase, and epileptic seizures, albeit
with an earlier onset and faster progression than the human disease. Our study provides
proof of principle that the advantages of the zebrafish over other model systems can be uti-
lised to further our understanding of the pathogenesis of CLN3 disease and accelerate drug
discovery.
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Introduction
Lysosomal Storage Disorders (LSDs) represent a group of 60 or more predominantly reces-
sively inherited monogenic disorders, the majority of which cause neurodegeneration (Parenti
et al., 2015). The neuronal ceroid lipofuscinoses (NCLs) or Batten disease are a group of LSDs
that comprise the most common, genetically heterogeneous, fatal neurodegenerative disorders
of children [1], with rare adult forms. The NCLs are characterised by variable age of onset,
visual failure, epileptic seizures, psychomotor retardation and dementia. Collectively, the NCLs
affect ~14 000 people worldwide [2]. To date, 13 genetic loci have been identified as causing
NCL and their classification is based upon the mutated gene and age of onset [3]. Each gene is
called CLN followed by a designated number, where CLN stands for ceroid-lipofuscinosis, neu-
ronal. For example when CLN3 is mutated, the most common onset is juvenile, so is referred to
as juvenile CLN3 disease. The incidence of CLN3 disease, the focus of this study, ranges from
0.25–7 per 100 000 in Europe [2].
The pathological hallmark of NCLs is storage material in lysosomes, but the content and
morphology of these storage vesicles vary. In CLN3 disease, subunit c of mitochondrial ATP
synthase (subunit c) is a major component of the storage material [4] but it is not known if
accumulation of storage material is protective or pathological, or if subunit c is a specific com-
ponent within the pathway in which CLN3 protein functions [5]; [4]; [6]. Indeed, very little is
known about the expression and function of the CLN3 protein (reviewed in [6] and [7]). CLN3
is a transmembrane protein, possibly ubiquitous throughout all tissues, and localised primarily
to the endosome and lysosome. The CLN3 protein has been linked to trafficking, autophagy,
osmoregulation, cell migration, cell morphology, proliferation and cell survival, but the pri-
mary function of this protein is unclear [6]; [7].
The presenting symptom in CLN3 disease is a loss of visual acuity, usually between 4 and 7
years old [2], leading to blindness within 2 to 10 years [8]. Cognitive decline, behavioural and
psychiatric problems follow. Epileptic seizures develop between 7 to 18 years and are predomi-
nantly of the tonic-clonic type, although partial complex and myoclonic seizures are also
observed. Seizures worsen and may frequently be, or become over time, refractory to medica-
tion [9]; [10]. Around puberty, motor symptoms evolve, manifesting primarily with extrapyra-
midal and cerebellar signs including hypokinesia, muscle rigidity, altered gait and imbalance,
resembling a parkinsonian phenotype [11]; [8]; [12]. Psychiatric problems include hallucina-
tions, depression, dementia and insomnia [13]. In addition to the neurological features, a car-
diac abnormality develops in the second decade of life [14]; [9], and the immune system is
compromised [15].
Symptoms are accompanied by a progressive reduction in brain weight (mainly attributed
to cerebral cortical atrophy) and white matter, enlargement of cerebrospinal fluid spaces, and
cerebellar atrophy [16]. Neuron loss is, however, selective. The substantia nigra often lacks pig-
ment (which may explain the Parkinsonism features) and there is loss of Purkinje cells and
granular cells in the cerebellum, and of granular cells in the dentate nucleus [5]. In addition,
neuronal loss and glial activation has been noted in the hippocampus [17]. However, detailed
quantitative information about neuropathological changes in human CLN3 disease is limited,
with qualitative studies restricted to autopsy material.
Mouse models have proved invaluable for studying the progression of CLN3 disease. Each of
the four genetic models recapitulates many features of the human disease [7]. Although there
are subtle mutation and strain dependent phenotypic differences in age of onset and severity, all
show a progressive onset of neurological deficits affecting vision, learning and memory and
motor function. These are associated with neuron loss in the retina, thalamus, cortex, cerebel-
lum, substantia nigra and striatum, which is preceded by glial activation [18]; [7]; [19].
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Treatments for CLN3 disease are palliative, relying largely on anti-epileptic drugs, which
have limited prolonged efficacy in this disorder [2], and L-DOPA [9]. Indeed, no disease modi-
fying therapy for CLN3 disease exists. Enzyme replacement therapy (ERT), gene therapy and
stem cell therapy, aimed at correcting for deficient proteins, are potential disease modifying
treatments for other forms of NCL [20]. However, as CLN3 disease is caused by mutations in a
transmembrane protein of unknown function that is not normally trafficked out of cells,
between cells or taken up from the extracellular space into cells, it is highly improbable that
protein delivered to the cerebrospinal fluid would be taken up by cells. Furthermore, introduc-
tion of functional protein by gene or stem cell therapy would need to be more widespread than
is currently possible. In contrast, NCLs caused by mutations in lysosomal enzymes such as
TPP1 (causing CLN2 disease) are amenable to ERT, due to the ability of the protein to cross-
correct (traffic to the extracellular space and then be taken up by other cells), and interim
results from the CLN2 disease ERT trial, in which recombinant protein is delivered to the CSF,
look promising (Clincaltrials.gov identifier NCT01907087; http://investors.bmrn.com/
releasedetail.cfm?ReleaseID=958565; [20]. However, small molecule therapy potentially pro-
vides a viable avenue for all of the NCLs [20]. To date, trials using mouse models of CLN3 dis-
ease have shown some symptomatic improvement after targeting the AMPA receptor with
EGIS-8332 [21]; [22] and the NMDA receptor with memantine [23]. Also promising is a
decrease in circulating autoantibodies to brain antigens after immune suppression with myco-
phenolate mofetil [24], leading to a phase 1 clinical trial of Cellcept (Clincaltrials.gov identifier
NCT01399047). Unfortunately, small molecule therapy development for CLN3 disease is
severely constrained by our lack of understanding of both the function of the CLN3 protein
and the disease pathogenesis. There is also a need for clinically predictive in vivo disease models
that are amenable to high-throughput small molecule screens.
Zebrafish are small freshwater teleosts that have become a valuable tool for disease model-
ling, particularly for neurodegeneration [25] and metabolic disease [26]. Tiny, transparent zeb-
rafish embryos and larvae exhibit rapid, oviparous development in high numbers making them
an excellent vertebrate tool to house in 96-well plates to facilitate in vivo high-throughput
screening and development of compounds using relevant, often automatable phenotypes such
as locomotion, or the monitoring of fluorescent reporters [27]; [26]; [25]; [28]. Indeed, we have
shown that automated locomotion assays reflect changes in motor function in the zebrafish
model of CLN2 disease (tpp1sa0011 mutant) [29] and we are currently exploiting these assays
for compound testing. Importantly, this method does not require knowledge of the normal or
abnormal function of the protein mutated in the disease, nor of the pathogenesis, making this
approach particularly suitable for CLN3 disease if a suitable zebrafish disease model was
available.
In the present study, we demonstrate that knockdown of cln3 in zebrafish recapitulates sev-
eral pathological features of the human disease including reduced survival, retinopathy, neuro-
degeneration, epileptiform activity and enlarged lysosomes with accumulation of subunit c.
Furthermore, we have identified phenotypes such as reduced proliferation in the retina and
axonal disorganisation. This model of CLN3 disease will enable us to further understand the
pathology of CLN3 disease and serve as a platform for compound testing prior to further test-
ing in more expensive and time-consuming mammalian models.
Materials and Methods
In situ hybridisation
The BC085653 clone containing the full-length zebrafish cln3 gene was used. Sense and anti-
sense RNA probes were transcribed by first linearising the plasmid with NotI and EcoRI. In
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vitro transcription was performed with SP6 and T7 RNA polymerases respectively, using a
digoxigenin (DIG) labelled mixture (Roche), according to the manufacturer (Roche). In situ
hybridisation was then performed, documented and manipulated as previously described [30].
Generation and maintenance of morphant zebrafish
Adult wild-type (WT) TupLF strain and transgenic Tg[HuC:GFP] zebrafish were housed in a
multi-rack aquarium system at the Royal Veterinary College. Zebrafish were reared at 28.5 ± 0.5°C
on a 14 hour light, 10 hour dark cycle. Local RVC Animal Welfare Ethics Review Board approval
was granted and a UKHome Office Project License was in place in accordance with the UK
Home Office Animals Scientific Procedures Act (1986).
Following adult breeding, embryos were incubated in the dark at 28°C, in ‘fish water’, con-
taining aquarium water and methylene blue (0.0002%). To inhibit pigment formation, embryos
were raised in 0.2 mM 1-phenyl-2-thiourea (PTU, Sigma) in fish water from 24 hours post-fer-
tilization (hpf) whilst still in their chorion. For live imaging of morphology, larvae were anes-
thetized with MS222 (0.016% w/v).
To generate cln3morphant embryos, morpholino (MO) anti-sense oligonucleotides against
cln3messenger RNA (mRNA) were pressure-injected into one-two cell stage zebrafish embryos
using a glass capillary injection needle. MOs (from Gene Tools, USA) targeting the start ATG
(cln3 ATGMO: CATtgcgactttcacaggagaaatg) or splice site (cln3 SPL MO: cagcaacCTAAACA
GAGATAATACA) of cln3, and the start site of p53 (p53MO: gcgcCATtgctttgcaagaattg;) [30],
as well as a control mismatch MO (cln3 ATGmismatch MO: CATTcCGAgTTTgACAcGAcA
AATG; mismatched nucleotides are shown in lower case) were used. MO sequences were sub-
jected to BLAST searches to confirm specificity.
Complementary DNA preparation, cloning and sequencing
To confirm mis-splicing by cln3 SPL MO, cDNA synthesis by reverse transcription of mRNA,
PCR, gel electrophoresis and sequencing was performed as previously described [29, 30]. cln3-
specific PCR primers (Invitrogen) used were (5’ to 3’): cln3 AF1 (5’UTR forward)-TGA
GCGATGATCATACACGA; cln3 AR1 (exon 3 reverse)- CGCTCAGCATCACCACATA; cln3
AR2 (exon 15 reverse)- AAGCAATTCCCAGACTGTCC.
Spontaneous coiling
Groups of 10 embryonic zebrafish still in their chorions were arrayed in a petri dish and
mounted on a Nikon SMZ1500 stereomicroscope (Nikon, UK). Three-minute recordings were
obtained with a DMK21AF04 camera (The Imaging Source, Germany) at a frame rate of 30
frames per second (fps) and recorded using Media Recorder (Noldus, distributed by Tracksys,
UK). Movies were obtained in .avi format and converted to .mp4 using Video Converter Pro
(Digiarty software, China). Videos were played back in slow motion using QuickTime Player
(Apple) and coiling or tail flicking events for each embryo counted.
Escape response
Individual larvae were placed in a petri dish and mounted on a Nikon SMZ1500 stereomicro-
scope. Fish were touched lightly with a pipette tip on the tail as many times as necessary to elicit
the escape response. Recordings were obtained with a DMK21AF04 camera at a frame rate of
30 fps and recorded using Media Recorder (Noldus). Movies were obtained as previously
described, and single frames extracted with SnapzPro X (Ambrosia, USA) for figure assembly.
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Whole-mount immunofluorescence
PTU-treated larvae were fixed overnight in 4% (w/v) paraformaldehyde (PFA) in 1 x PBS at
4°C. Subsequently larvae were stored in 100% methanol (MeOH) at -30°C. Larvae were rehy-
drated in a descending MeOH series, rinsed in PBST (PBS, 0.8% Triton X-100) and subjected
to proteinase K (15 ng/ml for 1 hour in PBS + 0.1% Triton™ X-100). Subsequently, the larvae
were fixed for 20 minutes in 4% paraformaldehyde/PBS, washed several times in PBST and
then blocked for 1 hour at RT in blocking reagent (PBST, 1% (v/v) DMSO, 10% normal goat
serum). Primary antibodies were diluted in incubation buffer (PBST, 1% (v/v) DMSO, 1% nor-
mal goat serum) and larvae incubated at 4°C overnight: mouse anti-acetylated α-tubulin
(1:1000) (Sigma), rabbit anti-PH3 (1:1000) (Upstate, distributed by EMDMillipore, UK), rab-
bit anti-subunit c (1:1000) (gift from Dr. J. Tyynelä) [29], mouse anti-LAMP1 (1:250) (Abcam,
UK), rabbit anti-GFAP (1:1000) (gift from Sam Nona and John Scholes) [31]. Larvae were
rinsed twice in PBST and then incubated four times for 15 minutes in PBST. Antibody blocking
was repeated by incubating larvae for 1 hour at RT in blocking reagent before applying the sec-
ondary antibody in incubation buffer for incubation at 4°C overnight: goat anti-mouse Alexa
568 (1:200), goat anti-mouse Alexa 546 (1:200), goat anti-rabbit Alexa 546 (1:200), goat anti-
rabbit Alexa 488 (1:200), goat anti-mouse Alexa 488 (1:200) (Invitrogen). Larvae were rinsed
twice in PBST and then cleared in 70% (v/v) glycerol in PBS. Fluorescent larvae were imaged
with a Leica SP5 confocal microscope (Leica, UK). All images for the same antibody were
acquired and manipulated in exactly the same way. Cells were quantified using the cell counter
plugin for Image J.
Retinal area
Single zebrafish larvae were mounted on microscope slides and imaged on a Nikon SMZ1500
stereomicroscope. Still images of the retinae were taken using a DMK21AF04 camera and cap-
tured using IC Capture (The Imaging Source, Germany). In Image J, the zebrafish retina was
encircled using the polygon tool and the area calculated.
Surface electroencephalogram (EEG)
Following the published protocol [32], zebrafish aged 4 days post-fertilisation (dpf) were incu-
bated in 2 mM Tubocurarine (Sigma, UK) until paralysed (at 5–20 minutes), rinsed and
mounted in 15 g/L type VII low melting point agarose (Sigma) in aquarium water for up to 1
hour EEG recording. They were terminated if the brain showed any opacity or poor perfusion,
there was considerable slowing of the heart rate, or if fish started to move. Prior to and during
all EEG recordings, all larvae were checked for good peripheral and cerebral blood circulation
and monitored to verify paralysis. Microelectrodes were pulled on a Zeitz puller (Zeitz, Ger-
many) from thin-walled borosilicate with filament (GC150 TF-7.5, Harvard Apparatus, UK),
manually broken and fire polished to a diameter of 10–15 μm. Electrodes were back-filled with
1 M NaCl, connected to a chlorinated silver wire and placed against the zebrafish head, above
the optic tectum. The potential difference between the recording electrode and a reference elec-
trode placed in the agarose close to the zebrafish was amplified 10,000× with a DAGAN 2400
amplifier (Dagan, USA), band pass filtered at 0.3–300 Hz and EEGs digitized at 2 kHz via a
PCI-6251 interface (National Instruments, UK) connected to a custom-made front end using
WinEDR V.3.0.8 software (John Dempster, University of Strathclyde, UK).
Regions of 20 seconds duration spanning spiking, or in the case of WT, baseline activity,
were extracted using WinEDR v.3.0.8, and the numerical values imported into Origin 7 (Origi-
nLab, USA) and subjected to a Fast Fourier Transformation (FFT) to generate the frequency
spectrum for the region of interest. Five regions of interest were extracted per zebrafish EEG
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and the resulting FFTs averaged to produce an average frequency spectrum for the fish in ques-
tion. These averaged FFTs were then further combined with other fish of the same treatment
group to produce an overall average spectrum. This frequency spectrum was then plotted
against amplitude to reveal the averaged spectral composition of the recorded EEG signals in
the frequency domain.
Vital stains
To visualise apoptotic cells, lysosomes and mitochondria, in vivo staining was carried out in
live, PTU-treated, manually-dechorionated, larvae with the vital dyes acridine orange (AO;
Sigma-Aldrich), LysoTracker red (LTR; Invitrogen) and Mitotracker red (MTR; Invitrogen),
respectively. Larvae were incubated at RT, in either 1.35 μMAO and 10 μM LTR, or 10 μM
MTR in PBS for thirty minutes on a rocker platform, protected from light. Larvae were rinsed
twice in PBS, mounted in 2% (w/v) low melting point agarose (Sigma) in aquarium water and
viewed with a Leica SP5 confocal microscope. All images for the same stain were acquired and
manipulated in exactly the same way.
Statistics
Statistical analyses were performed using Prism 6 (GraphPad software, USA). Specific tests for
each experiment are stated in the results. Statistical significance for all tests was referred to as
p0.05 , p0.01 , p0.001 , p0.0001 .
Results
Zebrafish cln3 is expressed in the developing zebrafish
cln3 gene expression was characterised in WT zebrafish using in situ hybridisation (Fig 1). cln3
expression was detected in newly fertilised WT embryos (Fig 1A), demonstrating deposition of
cln3mRNA into the egg by the mother, and is ubiquitously expressed until the 20 somite stage.
Subsequently, expression was observed in the retina and throughout the central nervous system
until 4 dpf. At 2 dpf expression was particularly strong in the prospective cerebellum (Fig 1G
and 1M). These data confirm that cln3 is expressed in development and could potentially give
an embryonic or larval phenotype when inactivated by gene knockout.
Protein conservation and efficacy of antisense morpholino knockdown of
cln3
CLUSTAL alignment showed that zebrafish Cln3 protein (446 amino acids) (GI:55925536)
shares an amino acid sequence similarity of 62% and identity of 49% with human CLN3 pro-
tein (438 amino acids) (GI:5801849) (Fig 2A). Given this level of conservation, we hypothe-
sised that loss of this protein in zebrafish is likely to have phenotypic consequences relevant to
human CLN3 disease.
cln3morphant zebrafish were generated by injecting MOs against cln3 into WT embryos.
No sufficiently specific antibody recognises endogenously expressed zebrafish Cln3 so we were
unable to confirm reduced translation and loss of Cln3 protein after cln3 ATGMO injection.
To confirm that cln3 SPL MO affected splicing of the cln3 gene, RT-PCR and sequencing was
conducted on WT and morphant larvae (Fig 2B). This analysis showed that cln3 SPL MO
caused aberrant splicing, producing three novel mRNA isoforms, each resulting in a stop
codon after exon two and is therefore predicted to produce a short protein that is unlikely to
have full function (Fig 2C).
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Both cln3morphants exhibit abnormal morphological characteristics
consistent with neurodegeneration
In human juvenile CLN3 disease, neuroimaging reveals ventricular dilation with atrophy of
the cerebral cortex, particularly the occipital lobes, and cerebellum [16]. In addition human
Fig 1. cln3 is expressed in the developingWT zebrafish. A-N) In situ hybridisation for cln3 (antisense)
shows its expression from the one cell stage through to 4 dpf. From 1 dpf expression is increasingly restricted to
the central nervous system. At 2 dpf cln3 expression is particularly strong in the mid-hindbrain boundary (arrow)
where the cerebellum is developing (G, H, M, N). (A’-L’) Experiments conducted using a cln3 sense probe
(sense) revealed the specificity of the antisense signal. Abbreviations: mhb, mid-hindbrain boundary.
doi:10.1371/journal.pone.0157365.g001
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patients display progressive morphological and functional cardiac abnormalities [14]. Bright-
field microscopy revealed that the morphology of the cln3 ATGMOmorphant brain at 4 dpf is
grossly abnormal, with changes noticeable from 32 hpf (Fig 3). At 4 dpf we observed a large
decrease in the size of the midbrain and hindbrain, the retina appeared smaller, the fourth ven-
tricle appeared dilated and the morphant heart lacked pigmented erythrocytes and had an
elongated appearance (Fig 3D and 3D’).
Further bright-field imaging was conducted at the earlier age of 32 hpf to observe how these
phenotypes progressed over time. At this earlier age, cln3 ATGMOmorphants already dis-
played abnormal development of the midbrain tectum, midbrain hindbrain boundary, and
reduced caudal hindbrain with enlargement of the fourth ventricle (Fig 3B and 3B’). At this
stage the morphant retinae also already appeared smaller and greyed, suggestive of cell death.
These findings are not only relevant to the human disease, but highlight the potential for such
morphants to reveal disease-related phenotypes.
Fig 2. Identification andmorpholino targeting of the zebrafish Cln3 gene. (A) CLUSTAL alignment indicates that zebrafish
Cln3 amino acid sequence (second row) is 62% similar and 49% identical to human CLN3 (first row). Black background indicates
identical residues shared between human and zebrafish, grey background indicates similarity, ‘-’ indicates a gap in the alignment.
(B) RT-PCR using primer pairs AF1-AR1 and AF1-AR2 (see C), followed by sequencing, confirmed that the cln3 SPLMO
affected mRNA splicing. Lanes one and two show the PCR product from cDNAmade from cln3 SPLMO injected embryos and
WT embryos respectively. Arrow in lane three points to the positive control, which is the PCR product generated using plasmid
containing cln3mRNA as a template. (C) i) the gene structure of WT cln3 showing the relative position of the PCR primers used.
ii) The WTmature mRNA. iii) Splice variants caused by injection of cln3 SPLMO. Key: lines, introns; boxes, exons; white boxes,
untranslated regions; red asterisk, stop codon.
doi:10.1371/journal.pone.0157365.g002
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Fig 3. cln3ATGMOmorphants have abnormal brain and heart morphology. (A, A’) 32 hpf normal
development of the WT forebrain, midbrain, hindbrain, retina and fourth ventricle. (B, B’) 32 hpf 1.6 ng cln3
ATGMOmorphants display abnormal development of all parts of the brain, a smaller retina, and enlargement
of the fourth ventricle. (C, C’) normal development of theWT tail, yolk, pericardial sac and heart at 4 dpf. The
WT brain completely fills the cranium. (D, D’) 1.6 ng cln3 ATGMOmorphants have a curved tail, and a larger
yolk and pericardial sac at 4 dpf. The heart has an elongated appearance and is lacking pigmented
erythrocytes. The fourth ventricle is enlarged and the mid- and hindbrain appear smaller. Lateral views.
Anterior is to left. Dorsal is up. Abbreviations: v, fourth ventricle; hb, hindbrain; mhb, mid-hindbrain boundary;
mb, midbrain, fb, forebrain, r, retina; t, tail; y, yolk; ps, pericardial sac; h, heart; (n = 4 per group). Lateral
views. Scale bars: A-D 250 μm; A’-D’ 100 μm.
doi:10.1371/journal.pone.0157365.g003
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Higher specificity and minimal toxicity from the cln3 ATGmorpholino
We compared cln3 ATGMO and cln3 SPL MOmorphants at a variety of doses using bright-
field microscopy. A higher dose of cln3 SPL MO (12 ng) was needed to cause the same mor-
phant phenotype as that caused by cln3 ATGMO (1.6 ng) at 4 dpf (S1 Fig). This is likely
because cln3 SPL MO disrupts splicing and therefore does not affect the cln3mRNA deposited
by the mother, whereas the cln3 ATGMO disrupts translation of both maternal and zygotic
cln3mRNA. Both morphants manifested small retinae, reduced brain size, pericardial oedema,
failure of the swim bladder to inflate, lack of yolk resorption and a curved tail (S1 Fig).
We reasoned that using a lower dose of MO is less likely to cause toxicity so all further
experiments were performed with the cln3 ATGMO. To confirm that the observed phenotype
was not caused either by off-target effects or general MO toxicity, we injected a 5 bp mismatch
MO (1.6 ng cln3 ATG mismatch MO) and a MO targeting p53 (8 ng p53MO) and found that
neither produced a morphological phenotype (data not shown). p53MOs are frequently used
because MO toxicity, if it occurs, is caused by activation of p53 which leads to apoptosis [33].
Co-injection of 8 ng p53MOwith 1.6 ng cln3 ATGMO did not rescue or reduce the cln3 ATG
MOmorphological (data not shown) or electroencephalography (EEG) phenotype (Fig 4),
indicating that the cln3 ATGMO did not cause p53-mediated toxicity. Hence, for all subse-
quent experiments the cln3 ATGMO was used and uninjected WT fish used as controls unless
otherwise stated.
cln3morphant EEGs show epileptiform activity
Surface EEG recording from the optic tectum [32] was used to investigate the possible presence
of epileptiform activity in 4 dpf cln3 ATGMOmorphants. EEGs recorded fromWT, cln3 ATG
MOmorphants and cln3 ATGMO (1.6 ng) + p53MO (8 ng) morphants (Fig 4A–4C) were
analysed by Fast Fourier Transformation (FFT) and the frequency spectrum was plotted
against amplitude to reveal the strength of the various frequency components in the original
EEG signal (Fig 4D–4F). This revealed increased activity at a frequency of 2–4 Hz (Fig 4E and
4F), the amplitude of which was significantly higher in both cln3 ATGMOmorphants and
those co-injected with p53MO (Fig 4G) (p<0.0001). This indicates synchronised neuronal
activity within this frequency range and reflects epileptiform activity.
cln3morphant survival is impaired
Human patients suffering from juvenile CLN3 disease die in the third or fourth decades of life
[12]. To examine the survival of cln3 ATGMOmorphants, a Kaplan-Meier survival analysis
was performed revealing that cln3 ATGMOmorphants (1.6 ng) had a median survival of 5 dpf
with a range of 1–6 dpf. In contrast, no WT larvae died within the time frame studied (Fig 5A).
Zebrafish injected with 2.9 ng of cln3 ATGMO had a median survival of 1 dpf with a range of
1–4 dpf (Fig 5B). The log rank (Mantel-Cox) analysis to test the null hypothesis of no differ-
ence in survival functions between WT and cln3MOmorphants confirmed that this difference
was statistically significant (p<0.0001). The premature death associated with knockdown of
cln3 can therefore be correlated with the reduced longevity of human patients, and the degree
of cln3 knockdown.
cln3morphants display abnormal motor behaviour
Most juvenile CLN3 disease patients experience seizures and myoclonic jerks and lose normal
motor function [10]; [16]. Zebrafish embryos first move at 17 hpf, when they develop sponta-
neous motor contractions causing coiling [34]. We hypothesised that coiling and later tail
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flicking may change in cln3morphants. The number of spontaneous coiling events at 24 hpf
and tail flicking at 48 hpf showed no difference between WT and cln3 ATGMO (1.6 ng) mor-
phants (p = 0.4566, 24 hpf and p = 0.3306, 48 hpf). However at 36 hpf, a significant difference
(p<0.0001) was seen, with morphants displaying considerably more tail flicks (Fig 5C–5E).
Although movements in cln3morphants were more frequent, they displayed weaker muscular
contractions—morphants were only able to weakly flick their tails, whereas WT tail flicks
caused the embryo to rotate within the chorion (compare S1 and S2 videos).
By 48 hpf, a touch to the end of the tail of a zebrafish typically results in movement away
from the source [35]. We determined the response of cln3 ATGMOmorphants to this touch
response test at 4 dpf. WT larvae responded very robustly to stimulus by forming a C-bend and
darting very quickly away (Fig 5F). In contrast, even though cln3 ATGMO (1.6 ng) morphants
were able to respond (though it often took several touches), they were unable to escape at high
velocity or perform a C-bend before escaping (Fig 5G). We also performed experiments at
lower doses and found that locomotion defects were always accompanied by morphological
defects (data not shown). These data support the theory that the loss of CLN3 protein in zebra-
fish causes motor abnormalities.
Fig 4. cln3 ATGMOmorphants display epileptiform activity in the 2–4 Hz range. Single channel surface EEG shows
frequent high amplitude spiking in both 1.6 ng cln3 ATGMOmorphants (B) and 1.6 ng cln3 ATGMO + 8 ng p53MO double
morphants (C) compared to WT (A). Fast Fourier transformation (FFT) was performed on 20 s representative samples, 5 times
per trace and an average produced per trace; an average FFT per genotype was then used to calculate the mean frequency
spectrum. The greatest spiking amplitude was observed between 2–4 Hz in the 1.6 ng cln3 ATGmorphants (E) and 1.6 ng cln3
ATGMO + 8 ng p53MO double morphants (F) compared to WT (D), and this was a statistically significant difference (G). WT
n = 5, cln3 ATGMO n = 6, cln3 ATGMO + p53MO n = 6.
doi:10.1371/journal.pone.0157365.g004
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Fig 5. Survival and activity are compromised in cln3 ATGMOmorphant zebrafish. (A-B) cln3 ATGMOmorphants die
prematurely. Progression of cln3 ATGmorphants demonstrated by monitoring cohorts of fish injected with 1.6 ng or 2.9 ng of
cln3 ATGMO and uninjectedWT siblings. (A) The Kaplan-Meier survival curve shows that all WT larvae survive beyond 6
dpf, whereas the majority of morphants injected with 1.6 ng cln3 ATGMO die between 3 and 6 dpf (median survival 5 dpf).
Log rank (Mantel-Cox) test p<0.0001 (n = 46WT and n = 23 morphants). (B) The Kaplan-Meier survival curve shows that all
WT larvae survive beyond 4 dpf, whereas the morphants injected with 2.9 ng cln3 ATGMO die between 1 and 4 dpf (median
survival 1 dpf). Log rank (Mantel-Cox) test p<0.0001 (n = 16WT and n = 31 morphants). Error bars indicate ± SE. (C-E)
Increased activity was observed in cln3 ATGMOmorphants at 36 hpf. Analysis of number of spontaneous coils or tail flicks
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Axonal tracts are aberrantly targeted in cln3morphants
In the zebrafish model of CLN2 disease, axonal tracts are highly disorganised [29] and,
although data is not available, this was also reported in the CLN2 disease mouse model [36].
We therefore explored axonal organisation in the cln3 ATGMOmorphants compared with
WT using immunofluorescence for acetylated α-tubulin (Fig 6). The results showed that cln3
ATGMO (1.6 ng) morphants aged 4 dpf had a marked lack of axonal organisation in the
brain, that was particularly marked by the loss of axons in the optic tectum and developing cer-
ebellum (Fig 6B and 6B’). It was also noted that the majority of axons seemed to remain near
their cell body, rather than extending to their respective targets (Fig 6B). Although an optic
nerve was present, it was thinner in comparison with WT, perhaps due to the observed reduc-
tion in retinal ganglion cells (Fig 6B”).
Astrocytosis is present in cln3morphants
The activation of astrocytes is a feature of NCL, including juvenile CLN3 disease [17] and is
also found in animal models of NCL, and in the case of Cln3mutant mice, occurs early in the
disease pathogenesis, prior to neuronal death [37, 38]. Immunofluorescence for glial fibrillary
acid protein (GFAP), a marker of astrocytes in normal zebrafish and of astrocytosis in reaction
to disease, showed GFAP positive cells present throughout the central nervous system in WT
and cln3 ATGMOmorphants (1.6 ng) (Fig 6C and 6C’). However, in cln3 ATGMOmor-
phants, ectopic GFAP, most likely due to astrocytosis, was apparent in the notochord (Fig 6D
and 6D’).
cln3morphants display considerable neuropathology
Since we determined that the axonal trajectories of cln3 ATGMOmorphants were abnormal
(Fig 6B and 6B’), we next explored the presence of additional neuronal pathology. cln3
ATGMO (1.6 ng) was injected into transgenic zebrafish embryos expressing GFP under the
control of the HuC promoter [39], a line used to label neuronal cell bodies (Fig 6E–6G and
6E’–6G’). At 3 dpf we observed that the morphants had an apparent reduction in neuron
number and a dramatic loss of order to their distribution (Fig 6F and 6F’), compared with
WT (Fig 6E and 6E’). Neuron loss was particularly evident in the midbrain, cerebellum, hind-
brain and retina. Many of the labelled cells in morphants were enlarged, peripheral (dashed
arrows in Fig 6F’), and lacking typical neuronal morphology (Fig 6G and 6G’). Although sim-
ilar cells can be seen in WT fish, the cells are less numerous and smaller (dashed arrows in
Fig 6E’).
Cellular proliferation is impaired and retinal area reduced in cln3
morphants
To determine if a general deficit in proliferation in the brain and retina, as seen in the zebra-
fish model of CLN2 disease [29], may also contribute to the cln3 ATGMOmorphant pheno-
type, immunofluorescence was carried out using an antibody against the mitotic M stage
within a 3 minute time period comparing 1.6 ng cln3 ATGMOmorphants with age matchedWT siblings was carried out at 24
hpf (C), 36 hpf (D) and 48 hpf (E). At 24 and 48 hpf the data show no significant difference in the number of coils or flicks. At 36
hpf the data show a significant difference in the number of flicks; p<0.0001 (n = 10 zebrafish per treatment group). Data
represent mean ± SD; results were evaluated using a 2-tailed unpaired Student’s t-test. (F-G) The cln3 ATGMOmorphant
escape response is diminished. (F) TheWT (control) fish aged 4 dpf respond to touch with a C-bend, a turn away from the
stimulus and rapid swimming (0.03 second intervals). (G) 1.6 ng cln3 ATGMOmorphants aged 4 dpf display a greatly
attenuated escape response (0.06 second intervals).
doi:10.1371/journal.pone.0157365.g005
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Fig 6. Neurons and glia are disrupted in cln3 ATGMOmorphants. (A-A”, B-B”) Immunohistochemical
staining for axons (acetylated α-tubulin) at 4 dpf. (A-A”) normal development of axons in WT larvae. (B-B”) 1.6
ng cln3 ATGMOmorphants have a complete absence of axonal organisation throughout the brain, with
axonal accumulation (B, dashed arrows), loss of the optic tectum and a narrowing of the optic nerve (B'',
dashed arrow). (A-A”, B-B”), anterior to the left; A, B, lateral view, dorsal up; A’, B’, dorsal view; A”, B” ventral
view. (C-C’, D-D’) Immunohistochemistry using antibodies to glia (glial fibrillary acidic protein, GFAP) at 4 dpf.
(C-C”) Normal staining in WT larvae. (D-D’) Ectopic GFAP is observed in the notochord in 1.6 ng cln3 ATG
MOmorphants (dashed arrow). Lateral view. Anterior to the left. Dorsal up. (E-E’, F-F’, G-G’) Transgenic
zebrafish expressing GFP under the control of the HuC promoter in neurons were injected with 1.6 ng cln3
ATGMO and observed at 3 dpf. (E-E’) In WT zebrafish, the normal structure of the developing brain and
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marker, phosphohistone H3 (PH3) [40] at 4 dpf. Analysis of this assay showed that in WT lar-
vae, proliferative cells are located throughout the retina, jaw and to a more limited extent, the
brain (Fig 7A and 7A’). However, in cln3 ATGMO (1.6 ng) morphant larvae, cellular prolifer-
ation appears reduced in the eye, and although not quantified, appears to be increased in the
brain (compare Fig 7A with 7B and 7A’ with 7B’). To investigate this apparent reduction in
retinal proliferation further, we quantified PH3 positive cells in the retinas of 4 dpf WT and
cln3 ATGMO (1.6 ng) morphant larvae (Fig 7C) and observed a significant reduction in cellu-
lar proliferation in the morphant retina. The mean number of proliferative cells in morphants
was 50% that of WT retinae, a statistically significant difference (p<0.0006). These data sug-
gest that impaired neuronal proliferation contributes to the cln3 ATGMOmorphant retinal
phenotype.
We next measured the retinal area of cln3 ATGMOmorphants at 4 dpf. These data showed
that the retinal area of the cln3morphants was significantly diminished by 77% compared to
WT (p<0.0001) (Fig 7D). These data showed that knockdown of cln3 significantly reduces reti-
nal area.
Apoptotic cell death and increased lysosomal storage were identified in
the cln3morphant brain
Juvenile CLN3 disease is characterised by loss of neurons, which is particularly marked in the
retina, thalamus, cerebral and cerebellar cortices, some of which has been attributed to apopto-
sis, and also by the lysosomal accumulation of lipopigments [12]; [41]. To examine if pro-
grammed cell death and lysosomal storage were present in cln3 ATGMOmorphants, acridine
orange and Lysotracker staining was carried out on live larvae prior to fluorescent confocal
imaging at 4 dpf. In WT larvae, a small amount of physiological programmed cell death was
shown (Fig 8A’) but very few lysosomal puncta were observed at this magnification (Fig 8A”).
cln3 ATGMO (1.6 ng) morphants showed a considerable level of programmed cell death in
the brain that localised predominantly to the optic tectum (Fig 8B’), but, as in WT larvae, few
lysosomes were brightly stained (Fig 8B”). However, when a larger dose of 2.9 ng cln3 ATG
MO was injected, an even greater amount of programmed cell death occurred in the forebrain,
midbrain and retina (Fig 8C’). Abnormal hypertrophy of lysosomes was also observed in larvae
injected with the higher dose of morpholino (Fig 8C”) and this was shown to co-localise with
acridine orange staining in some regions, particularly in the forebrain (Fig 8D”), which may
indicate the phagocytosis of dead neurons.
Subunit c of the mitochondrial ATP synthase co-localises with
lysosomes
A characteristic component of most of the NCLs, including CLN3 disease, is the lysosomal
accumulation of subunit c, which makes up almost 50% of the storage mass (Palmer et al.,
1995). To test if cln3 ATG morphants accumulate subunit c, immunofluorescence was carried
out on 4 dpf larvae using antibodies against subunit c and the lysosomal marker lysosomal-
associated membrane protein 1 (LAMP1). Although subunit c and LAMP1 are ubiquitously
retina can be observed. (F-F’) In morphants, there appear to be fewer neurons and the normal brain structure
is lost. Many GFP-positive cells were enlarged and found nearer the surface of the brain (F’, dashed arrows).
(G-G’) When the morphology of these enlarged cells was examined further, they lacked typical neuronal
morphology. Lateral view. Anterior to the left. Dorsal up. Abbreviations: cb, cerebellum, fb, forebrain; hb,
hindbrain; ot, optic tectum; on, optic nerve. A-G” (all images) Z projection. Scale bars: 100 μm. n = 4 per
group.
doi:10.1371/journal.pone.0157365.g006
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Fig 7. Cellular proliferation is abnormal in cln3 ATGMOmorphant zebrafish. (A, A’) Proliferation,
assayed at 4 dpf using anti-PH3 (a marker of proliferative cells in mitotic M phase), is observed throughout
the 4 dpf WT retina, jaw and the brain. (B, B’) A marked reduction in the amount of cellular proliferation
throughout the retina can be seen in the 1.6 ng cln3 ATGMOmorphant. Although not quantified, it appears
that proliferation in the morphant brain (B) is increased compared to WT. Confocal images are Z-projections.
Scale bar: 100 μm (A, A’, B) and 50 μm (B’). Lateral views. Anterior is to the left. Dorsal is up. (C)
Quantification of these data show that the number of proliferating cells in the morphant retina is significantly
reduced from 100.3 cells in WT to 50.3 cells in morphants; ***p<0.0006 (n = 3 zebrafish per group). (D)
Quantification demonstrating a significantly reduced mean retinal area in the morphants (0.0566 mm2 for WT
retinae compared to 0.0135 mm2 for morphant retinae; ****p<0.0001 (n = 10 zebrafish per group)). (C, D)
Data represent mean ±SD; results were evaluated using a 2-tailed unpaired Student’s t-test.
doi:10.1371/journal.pone.0157365.g007
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Fig 8. Apoptotic cells and lysosomal storage were found in the cln3ATGMOmorphant brain. Acridine
orange and Lysotracker staining was carried out on live WT and cln3 ATGMOmorphant zebrafish aged 4 dpf.
(A-A”) WT fish showed low levels of programmed cell death in the brain and very little bright lysosomal staining.
(B-B”) Morphants injected with 1.6 ng of cln3 ATGMO had increased levels of programmed cell death (acridine
orange, bright green) in the brain, this localised particularly to the optic tectum, but only a slight increase in
lysosomal staining (red). (C-C”) Morphants injected with 2.9 ng of cln3 ATGMO showed very high levels of
programmed cell death in the forebrain, midbrain, retina and yolk-body boundary; lysosomal hypertrophy was
also observed. (D-D”) Morphants injected with 2.9 ng of cln3 ATGMO exhibit abundant apoptotic bodies in the
forebrain that often co-localises with lysosomes (arrows). Bright green, acridine orange in apoptotic bodies;
Red, Lysotracker red in lysosomes. Abbreviations: ab, apoptotic body; lys, lysosome; ot, optic tectum. A-A",
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present, co-localisation of these markers in enlarged puncta showed that subunit c accumulates
in lysosomes in the cln3 ATGMOmorphant notochord at 4 dpf (Fig 9B and 9B”), but not in
WT larvae (Fig 9A and 9A”).
Mitochondria in cln3morphants were abnormal
In several of the NCLs, including CLN3 disease, abnormally enlarged mitochondria and reduced
activity of respiratory chain complexes has been reported [42]. Mitochondria were therefore
stained in live zebrafish larvae at 4 dpf using Mitotracker Red [43]. InWT larvae (Fig 9C and 9C’)
individual mitochondria can be resolved, some of which are rounded and some elongated. In cln3
ATGMO (1.6 ng) morphants the stain was not efficiently taken up by the mitochondria, but
remains diffuse, thus indicating that they have reduced membrane potential (Fig 9D and 9D’).
Discussion and Conclusion
In this study, we successfully knocked down cln3 in zebrafish and demonstrated a range of
embryonic and larval phenotypes relevant to CLN3 disease: patient signs reproduced include
seizures, motor deficits and premature death. The expected pathological changes observed
included programmed cell death, astrocytosis, reduced neurons, reduced neuronal projections,
lysosomal storage of subunit c and mitochondrial deficits. In relation to expected changes in
morphology, we demonstrated reduced brain and retinal tissue, expanded brain ventricles, and
cardiac defects. These combined features confirm that zebrafish cln3morphants do indeed
recapitulate many features of CLN3 disease, despite occurring during early development and
progressing very fast. In patients, onset is juvenile and progression is slow, resulting in many
patients living to their second or third decade [2]. Nevertheless, this zebrafish model will be a
useful tool for studying this condition as discussed later. In particular, we have documented
epileptiform activity, which has not been observed as a natural occurrence in mouse models of
CLN3 disease. In two mouse models of CLN3 disease, increased susceptibility to seizure induc-
tion has been noted [18] but EEG has not been performed to confirm natural seizure suscepti-
bility. As seizures are a key symptom of the human disease, zebrafish cln3morphants may be
particularly useful for studying this.
Our data demonstrated an increase in programmed cell death in the brain of cln3mor-
phants (1.6 ng MO) when lysosomal storage was not evident, suggesting either that neurons
are dying in the absence of storage or that there is a lysosomal acidification defect reducing
lysosomal uptake of Lysotracker, as suggested in mouse CbCln3ΔbCln3 cells [44] and patient
fibroblasts [45]. However, at a higher dose of morpholino (2.9 ng), increased Lysotracker stain-
ing due to lysosome hypertrophy indicates that lysosomal pH is unlikely to be significantly
affected. We suggest that the larger lysosomes reside in microglia: as phagocytic cells, microglia
are likely to have relatively large lysosomes, and when deficient in cln3, they are expected to be
even larger. In support of this, we observed GFP from neurons (HuC:GFP) in cells with mor-
phology that could indicate microglia or phagocytes—perhaps microglia have phagocytosed
debris from apoptotic neurons but are unable to degrade the GFP. Indeed, recent evidence sup-
ports the hypothesis that the microglial response promotes disease progression in a mouse
model of CLN3 disease [46].
Although EEG revealed high amplitude spiking events in cln3morphants, reflecting epi-
leptiform activity perhaps similar to that seen in humans [10], we were not able to correlate
B-B", C-C” are Z projections. D-D” are the same Z slice. Lateral views. Anterior to the left. Dorsal up. The scale
bars represent 200 μm and apply to all panels.
doi:10.1371/journal.pone.0157365.g008
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Fig 9. Subunit c accumulates in lysosomes, andmitochondria are compromised in cln3ATGMO
morphants. (A-A", B-B") Immunohistochemical staining for lysosomal associated membrane protein 1
(LAMP1, green) and subunit c of the mitochondrial ATP synthase (subunit c, red) at 4 dpf. (A-A”) WT. (B-B”) 1.6
ng cln3 ATGMOmorphants. In morphants, lysosomes appear larger (B, dashed arrow), subunit c accumulates
(B’, dashed arrow) and they co-localise (B”, dashed arrows). Abbreviations: nc, notochord. Z slice. Lateral view.
Anterior to left. Dorsal up. Scale bars: 50 μm. (C-C’, D-D’) Mitotracker stain labelling mitochondria in superficial
cells of the eye at 4 dpf. (C-C’) WT. (D-D’) 1.6 ng cln3 ATGMOmorphant. In WT cells, many individual
mitochondria are observed, whereas in morphant cells the stain has not been accumulated by mitochondria
suggesting loss of mitochondrial membrane potential. Z slice. Lateral view. Scale bars: C, D 25 μm; C’, D’
10 μm.
doi:10.1371/journal.pone.0157365.g009
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this with movement as at the stage when we can perform EEG, cln3 morphants are less able
to move. The increased tail flicking activity at 36 hpf may be related to seizure or myoclonic
activity, as proposed for the zebrafish model of EAST syndrome [32], but could also be due to
developmental delay and a prolonging of the earlier spontaneous coiling phenotype. Unfortu-
nately, at this time, it is not possible to perform EEG on 36 hpf zebrafish to confirm seizures.
On the other hand it is not possible to carry out EEG on moving fish: the artificial paralysis
required to avoid movement artefacts means that spiking events cannot be correlated with
ictal (during a seizure) or inter-ictal (not correlating with a seizure) motor activity. A further
limitation is that, in contrast to EEG from humans, in which recordings from multiple elec-
trodes are taken, our technique does not allow differentiation between generalised or partial
seizures.
The significance of the increased amplitude spiking around 2–4 Hz in cln3morphants is
unclear, but has also been shown in other zebrafish epilepsy models [32]. Synchronisation in
this range (3 Hz) is characteristic of a number of human epilepsies including idiopathic gener-
alised epilepsies (age-related), childhood absence epilepsy (pyknolepsy), juvenile absence epi-
lepsy and epilepsy with myoclonic absences (Commission on Classification and Terminology
of the International League Against Epilepsy, 1989). Furthermore, spike and wave epileptic sei-
zures in humans are characterised by 3 Hz oscillations, resulting in sudden-onset generalised
seizures and this pattern is also seen in various animal models including cats, rats, mice and
monkeys [47]. It may be that this 3 Hz activity is related to inhibitory thalamocortical connec-
tions and the involvement of both GABAA and GABAB receptors [47]. We postulate that the
EEG results in this study are relevant to human disease and may be used to investigate seizure
pathogenesis further and test for anti-epileptic drugs beneficial in CLN3 disease.
We have also demonstrated that the phenotype is progressive in cln3morphants, although
it is difficult to compare zebrafish and human ages. CLN3 patients lose mobility by their teen-
age years [16] compared to the severe motor deficit in cln3morphants at 4 dpf, when, although
able to sense touch, their ability to escape was greatly attenuated. Earlier in development, how-
ever, cln3morphants were capable of moving, suggesting a progressive loss of motor function.
Spontaneous coiling arises from a primitive spinal circuit, as demonstrated by the fact that
lesions of the hindbrain have no effect on these behaviours but do affect touch response and
swimming [34]. cln3morphants are able to sense touch to the tail, although several touches
were necessary to elicit a response, indicating that trigeminal neurons and Rohon-Beard neu-
rons are at least partially intact. Both these categories of sensory neurons project to the hind-
brain where they synapse with reticulospinal neurons [34]. Together these data suggest that the
reticulospinal system is compromised, which is supported by the observation that the hind-
brain is smaller than in WT larvae. A marked atrophy of the cerebellum was also observed in
cln3morphants, and this is likely to contribute to the failure to integrate sensory and motor
functions.
In addition to expected phenotypes, this study has revealed reduced proliferation in the ret-
ina as a potential contributing factor to the smaller retina in cln3morphants, similar to what is
seen in zebrafish tpp1sa0011 mutants (model of CLN2 disease; [29]). cln3morphants also have a
larger yolk sac than WT. Absorption of the yolk depends upon autophagy [48] and larvae with
defective autophagy such as cathepsin Dmutants [49] have large yolks, as do tpp1sa001 mutants
[29]. This suggests that autophagy may be altered in zebrafish cln3morphants, as in the CLN3
disease mouse model [50], patient-derived iPSCs [51] and patient fibroblasts [52], however we
cannot exclude an effect of overall developmental delay.
We propose that this zebrafish model of CLN3 disease may prove particularly useful for
finding new small molecule therapies through in vivo screening, due to its small size at phe-
notypic onset which enables more animals to be treated and assayed at a time [28]. Both anti-
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epileptic drugs and disease-modifying drugs are needed for CLN3 disease. In zebrafish cln3
morphants, seizures were preceded by an increase in tail flicking, and we suggest that this
phenotype could be exploited for compound screening using an automated activity or move-
ment assay [53]. Furthermore, automated fluorescent assays for programmed cell death, lyso-
somes or microglia could be employed to find other potential therapies [54]. Hence, this new
model of CLN3 disease could fill the need for an in vivomodel suitable for high-throughput
screening.
Supporting Information
S1 Fig. Abnormal morphology was observed using two different cln3morpholinos at 4 dpf.
(A, A’) WT. (B, B’) 1.6 ng cln3 ATGMO. (C, C’) 12 ng cln3 SPL MO. Morphant larvae (B, B’,
C, C’) showed small retinas, small brain, pericardial oedema, a large yolk sac and abnormal tail
curvature (dashed arrows) compared to WT (A, A’). Abbreviations: r, retina; ps, pericardial
sac; y, yolk; t, tail; fb, forebrain; mb, midbrain; hb, hindbrain. Lateral views. Anterior to left.
Dorsal up. Scale bars: A-C 250 μm; A’-C’ 125 μm.
(TIF)
S1 Video. Video of normal coiling activity in 36 hpf WT zebrafish.
(MP4)
S2 Video. Video of abnormal coiling activity in 1.6 ng cln3 ATGMOmorphant 36 hpf zeb-
rafish, demonstrating weak contractions.
(MP4)
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